Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare

Indomethacin [53-86-1]

Stampa

Cat# T0458-1g

Size : 1g

Marca : TargetMol

Richiedere ulteriori informazioni

Indomethacin

(Synonyms: Indomethacine, Indometacine, Indometacin, Indocin) Copy Product Info

Indomethacin is an orally active nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase enzymes COX-1 and COX-2, with IC₅₀ values of 18 nM and 26 nM, respectively. It exhibits good blood-brain barrier permeability and shows significant anti-inflammatory, anti-tumor, and anti-infective activities. Indomethacin is widely used in research related to cancer, inflammation, and viral infections, and is also commonly used to induce gastric ulcer models in animals.

Cas No. 53-86-1

For research use only—not for human use. No sales to individuals. Use as intended only.

Batch Information

Select Batch

Purity:99.76%

Color:White

Resource Download

COA HNMR LCMS

Product Information

Bioactivity

Description	Indomethacin is an orally active nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase enzymes COX-1 and COX-2, with IC₅₀ values of 18 nM and 26 nM, respectively. It exhibits good blood-brain barrier permeability and shows significant anti-inflammatory, anti-tumor, and anti-infective activities. Indomethacin is widely used in research related to cancer, inflammation, and viral infections, and is also commonly used to induce gastric ulcer models in animals.
Targets & IC50	COX-1:0.28 μM, COX-2:14 μM
In vitro	METHODS: Human gastric cancer cells AGS were treated with Indomethacin (100-500 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Indomethacin increased LC3-II protein levels in AGS cells, which may be a result of induction of autophagy or inhibition of lysosome-dependent autophagic degradation. [1] METHODS: Human tumor cells HT29 and A431 were treated with Indomethacin (1-10 µM) and EGF (25 ng/mL) for 24-48 h. Cell migration was detected by wound-healing assay. RESULTS: Indomethacin inhibited HT29 cell migration. After treating A431 cells with EGF only, the wound closed within 24 h, but the wound remained open after 24 h of treatment with Indomethacin. [2]
In vivo	METHODS: To test the antitumor activity in vivo, Indomethacin (1 mg/kg) was administered by gavage to CDF1 mice bearing Colon 26 xenografts twice daily for 7-21 days. RESULTS: Mean tumor weight was significantly lower in both the long-term and short-term Indomethacin administration groups, serum immunosuppressive acidic protein levels were significantly lower, serum IL-6 levels were also significantly lower, and prostaglandin E2 levels in tumor tissues were significantly lower than those in the control group. [3]
Synonyms	Indomethacine, Indometacine, Indometacin, Indocin
Disease Modeling Protocol	Small intestine inflammation model Modeling Mechanism： Indomethacin inhibits cyclooxygenase (COX) activity, reduces prostaglandin (PGE) synthesis, and disrupts the small intestinal mucosal repair function. Simultaneously, it damages tight junction proteins, increases intestinal permeability, and triggers local inflammation mediated by gut microbiota and intestinal contents, inducing the release of pro-inflammatory factors such as TNF-α and IL-6. Furthermore, it induces oxidative stress, reduces glutathione (GSH) and antioxidant enzyme (SOD, GPX) activity, and increases lipid peroxidation products (MDA) and total oxygen saturation (TOS), ultimately leading to small intestinal villus structure destruction, erosion, ulceration, and inflammatory infiltration. Related Products： Indomethacin (T0458) Modeling Method： Experimental Subject： Rats, Wistar, Female, 15 weeks old, Body weight 160–200 g Dosage and Administration Route： 25 mg/kg indomethacin, dissolved in 0.9% saline, administered via gastric lavage Dosing Frequency and Duration Model： Single dose Validation： The small intestinal tissue showed disordered villus structure, erosion and ulceration, and inflammatory cell infiltration, with a significantly elevated total pathological damage score; the levels of TNF-α and IL-6 in the small intestinal tissue were significantly elevated; the content of GSH and the activities of SOD and GPX were decreased, while the levels of MDA and TOS were increased; and the total antioxidant level (TAS) of the tissue was decreased. Precautions： All rats were anesthetized and sacrificed 6 hours after modeling, and the small intestine tissue was rapidly separated. References：Secgin S, et,al. Thiamine pyrophosphate may protect indomethacin-induced small intestinal enteropathy in rats by inhibiting intestinal inflammation and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct;398(10):14441-14450. Gastric ulcer model Modeling Mechanism： Indomethacin inhibits the synthesis of COX-1/COX-2 prostaglandins, leading to decreased gastric mucosal defense, increased inflammation and oxidative stress, and thus causing gastric mucosal damage and ulcer formation. Related Products： Indomethacin (T0458) Modeling Method： Experimental Subject： Rats, Wistar, Equal numbers of males and females, 200–220 g Dosage and Administration Route： 30 mg/kg, dissolved in distilled water and administered via gavage Dosing Frequency and Duration Model： Single dose Validation： Serum EGF and PGE2 concentrations were significantly decreased. Immunohistochemical results showed that the expression levels of COX-1 and COX-2 in the gastric mucosa were significantly downregulated, and there was significant gastric mucosal epithelial shedding, edema, and inflammatory cell infiltration. The gastric mucosal injury index was significantly increased. Precautions： Before administration to all animals 24 hFasting was implemented. In the prevention experiment, animals were sacrificed 6 hours after gavage administration of indomethacin; in the treatment experiment, animals were administered the drug for 3 days after modeling, followed by a 24-hour fast before being sacrificed. References：Fang YF,et,al.Effect of Hydrotalcite on Indometacin-Induced Gastric Injury in Rats. Biomed Res Int. 2019 Apr 11;2019:4605748.

Chemical Properties

Molecular Weight	357.79
Formula	C₁₉H₁₆ClNO₄
Cas No.	53-86-1
Smiles	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Relative Density.	1.32g/cm3

Storage & Solubility Information

Storage

Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 104 mg/mL (290.67 mM), Sonication is recommended.

Ethanol: 17.9 mg/mL (50.03 mM), Heating is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.58 mg/mL (10.01 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.7949 mL	13.9747 mL	27.9494 mL	139.7468 mL
5 mM	0.5590 mL	2.7949 mL	5.5899 mL	27.9494 mL
10 mM	0.2795 mL	1.3975 mL	2.7949 mL	13.9747 mL
20 mM	0.1397 mL	0.6987 mL	1.3975 mL	6.9873 mL
50 mM	0.0559 mL	0.2795 mL	0.5590 mL	2.7949 mL

DMSO

	1mg	5mg	10mg	50mg
100 mM	0.0279 mL	0.1397 mL	0.2795 mL	1.3975 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

T0757-100mg

Omeprazole [73590-58-6]

100mg